Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for the treatment of autoimmune diseases. The company operates within the biotechnology and cell therapy industries, with a specific emphasis on applying chimeric antigen receptor T cell (CAR‑T) technology beyond oncology. Its core strategy is to selectively eliminate pathogenic immune cells believed to drive severe autoimmune conditions, with the goal of inducing durable remission without chronic immunosuppression.
The company’s primary revenue activity is research and development, as it does not currently have approved commercial products. Cabaletta Bio’s lead therapeutic program is CABA‑201, a fully human CD19‑directed CAR‑T cell therapy being evaluated across multiple autoimmune indications. The company primarily serves patients with severe, refractory autoimmune diseases and positions itself as a pioneer in translating oncology-derived CAR‑T platforms into immunology. Cabaletta Bio was founded in 2017 as a spin‑out from academic research conducted at the University of Pennsylvania and completed its initial public offering in 2019, becoming listed on the Nasdaq Global Market under the ticker CABA.
Business Operations
Cabaletta Bio operates as a single-reportable-segment company centered on the discovery, development, and clinical advancement of autologous CAR‑T cell therapies. Its operations are organized around its proprietary CAR‑T technology platform, which includes internal capabilities for clinical development, translational research, and regulatory strategy. The company generates no product revenue and relies on equity financing and cash reserves to fund operations.
The company’s pipeline is anchored by CABA‑201, which is being evaluated in multiple investigator‑initiated and company-sponsored clinical trials across indications such as systemic lupus erythematosus, myositis, and systemic sclerosis. Cabaletta Bio conducts manufacturing primarily through external contract manufacturing organizations rather than owning large-scale production facilities. It maintains research collaborations with academic institutions, including continued scientific ties to the University of Pennsylvania, though no material revenue-generating joint ventures have been disclosed in public filings.
Strategic Position & Investments
Cabaletta Bio’s strategic direction centers on establishing CAR‑T therapy as a viable, potentially curative treatment modality for autoimmune diseases. The company’s growth initiatives are focused on expanding the clinical footprint of CABA‑201 across multiple indications, generating proof‑of‑concept data, and advancing next‑generation CAR‑T constructs designed to improve safety, durability, and scalability.
The company has not completed any transformative acquisitions and instead invests primarily in internal research and clinical development. Its portfolio is concentrated, with CABA‑201 representing the most advanced asset, while earlier-stage preclinical programs explore alternative targets and engineered cell approaches. Emerging areas of focus include refining lymphodepletion regimens and exploring broader applicability of B‑cell depletion strategies in autoimmunity. Data on long‑term commercial manufacturing investments remains inconclusive based on available public sources.
Geographic Footprint
Cabaletta Bio is headquartered in the United States, with its principal executive offices located in Pennsylvania. Its operations are primarily U.S.-based, encompassing corporate management, clinical development oversight, and regulatory activities. The majority of its clinical trials are conducted at specialized academic and medical centers within North America.
While the company does not maintain significant permanent international facilities, its clinical and scientific influence extends to Europe and other regions through globally relevant clinical data and participation by non‑U.S. research sites in certain studies. International commercial operations have not yet been established, reflecting the company’s pre‑commercial stage of development.
Leadership & Governance
Cabaletta Bio was founded by physician‑scientists with expertise in immunology and cell therapy, and its leadership team emphasizes rigorous clinical science, patient safety, and disciplined capital allocation. The company is governed by a board of directors with experience in biotechnology development, public company governance, and life sciences investing. Management’s stated vision centers on delivering transformative, one‑time therapies for patients with severe autoimmune diseases.
Key executives include:
- David J. Chang, M.D., Ph.D. – President and Chief Executive Officer
- Frank A. Sinicrope – Chief Financial Officer
- Rebecca S. Runkle, Ph.D. – Chief Scientific Officer
- Steven Nichtberger, M.D. – Chief Medical Officer
Leadership philosophy emphasizes data-driven decision-making, close collaboration with academic partners, and advancing therapies through clearly defined clinical milestones while maintaining regulatory and scientific rigor.